We envisage that restoration of CTRP9 levels in diabetic cardiomyopathy might be a novel therapeutic strategy, but care must be taken that systemic insulin resistance is not aggravated by this approach. This evidence concerns the gene C1QTNF9 and diabetic cardiomyopathy.